vegfr-2

JNJ-38158471 (CS-2660), a highly selective, orally available, well tolerated VEGFR2 inhibitor with IC50 of 40 nM, inhibits closely related tyrosine kinases such as Ret and Kit with IC50 of 180 nM and 500 nM.

VEGFR-2-IN-6 (WO 02 059110, example 64) is a potent inhibitor of VEGFR2, a crucial receptor involved in the regulation of angiogenesis [1].

VEGFR-2-IN-29 is a VEGFR2 inhibitor.

VEGFR-2-IN-9 (KDR-in-4) is a potent KDR VEGFR2 inhibitor with an IC50 of 7 nM, suitable for breast cancer research.

TIE-2 VEGFR-2 kinase-IN-5 (TIE-2 and VEGFR-2 tyrosine kinase receptor inhibitor) is a potent agent with anti-angiogenic activity, commonly used in biomedical research focused on angiogenesis.

VEGFR-2 InhA-IN-1, a dual inhibitor based on pyrazole, targets InhA and VEGFR, exhibiting both anti-tuberculosis and anti-angiogenic properties. It demonstrates effective antibacterial activity against the Mycobacterium tuberculosis H37Rv strain (MIC = 6.25 μg mL) and significantly suppresses VEGFR-2 activity (IC 50 = 15.27 nM).

VEGFR-2-IN-57 (compound 6n) exhibits significant cytotoxicity on HUVEC cells, with an IC50 value of 28.77 nM.

VEGFR-2-IN-53 (Compound 15w) is an inhibitor of VEGFR-2 with an IC50 value of 4.34 μM. It induces cell apoptosis (Apoptosis) and inhibits angiogenesis by blocking VEGFR-2 activity and preventing cell migration. Additionally, it shows an IC50 of 3.87 μM in inhibiting the growth of MCF-7 cells, making it pertinent for research in cancer therapeutics.

VEGFR-2-IN-55 (Compound 30) is an effective VEGFR-2 kinase inhibitor with an IC50 of 1.24 nM and exhibits anti-tumor activity.

VEGFR-2-IN-56 (compound 12e) exhibits the strongest inhibition activity against VEGFR-2, with an IC50 value of 45.9 nM.

VEGFR-2 AKT-IN-2 (Compound 5) is an inhibitor of VEGFR-2 AKT, with an IC50 of 0.061 μM for VEGFR in human liver cancer cells. It reduces total and phosphorylated AKT in cells, increases BAX and caspase-3 levels, and decreases Bcl-2, thereby inducing apoptosis. Additionally, VEGFR-2 AKT-IN-2 halts the cell cycle at the S phase and inhibits the growth of human liver cancer cells.

VEGFR-2-IN-59 (Compound 3h) is an inhibitor of VEGFR2 with an IC50 of 3.73 µM. It exhibits cytotoxicity in cancer cell lines A549, HT-29, A375, MCF7, and NHDF, with IC50 values of 20.91, 19.70, 9.63, 17.43, and 20.71 μM, respectively. VEGFR-2-IN-59 also inhibits tubular structure formation and demonstrates anti-angiogenic properties.

VEGFR-2-IN-64 (Compound 28) is an inhibitor of VEGFR2 with an IC50 of 27.8 nM. It suppresses the proliferation of cancer cells A549, T-47D, and Caco-2, exhibits anti-migration and anti-colony formation activities in T-47D cells, and induces apoptosis in T-47D cells.

VEGFR-2-IN-60 (compound 5c) is a potent VEGFR-2 inhibitor with an IC50 of 1.07 nM and exhibits cytotoxic activity against HCC1806, Hela, and A549 cell lines.

VEGFR-2-IN-62 (Compound 3f) is a potent inhibitor of VEGFR-2, with an IC50 value of 0.0557 μM. It inhibits cell proliferation and induces apoptosis (Apoptosis), making it useful for cancer research.

VEGFR-2-IN-58 (Compound 7b) is a VEGFR-2 inhibitor with an IC50 of 42.5 nM. It shows selective cytotoxicity against cancer cells, induces cell cycle arrest at the G2 M phase, and triggers apoptosis by increasing BAX expression and decreasing Bcl2 expression. Additionally, VEGFR-2-IN-58 hampers cancer cell wound closure.

VEGFR-2-IN-63 (Compound 12b) is an inhibitor of VEGFR2, reducing 87.2% of VEGFR-2 activity at 10 μM. It exhibits anti-proliferative activity against various cancer cells, with IC50 values of 6.5 μM for HCT116, 2.1 μM for MCF7, and 4.1 μM for PaCa2.

CAIX VEGFR-2-IN-3 (Compound 6i) is an inhibitor of Carbonic Anhydrase IX and VEGFR-2, with IC50 values of 41 and 48 nM, respectively. It exhibits anticancer activity by inhibiting the growth of MCF-7 breast cancer cells (IC50 of 22.33 μM) and mouse fibroblast cell line 3T3, where cell viability is reduced to below 40% at a concentration of 100 μM. This compound is applicable for research in the field of cancer treatment.

VEGFR-2-IN-61 (Compound 7b) is an inhibitor of VEGFR-2 with an IC50 of 2.83 µM. It effectively inhibits the proliferation of various cancer cells, including MCF-7 cells, with an IC50 of 2.12 µM. Additionally, VEGFR-2-IN-61 suppresses cell migration and induces oxidative stress and apoptosis in MCF-7 cells.

VEGFR-2-IN-65 (Compound 07) functions as a VEGFR-2 inhibitor. It forms hydrogen bonds with Cys180 and can inhibit tube formation in HUVECs.

VEGFR-2-IN-5 (UNC0064-12), multikinase inhibitor and has a -NH2 terminal linker for further synthesis.

VEGFR-2-IN-66 (Compound 6) is an orally active VEGFR-2 inhibitor with an IC50 of 0.509 µM and an IC50 value of 7.48 μM for inhibiting MCF-7 cell proliferation. Its anticancer activity is exerted through cell cycle arrest, induction of apoptosis (Apoptosis), and modulation of gene expression, making it suitable for breast cancer research.

VEGFR-2-IN-67 (Compound 6b) functions as an inhibitor of vascular endothelial growth factor receptor 2 (VEGFR-2), with IC50 values of 5.91 µM for MDA-231 cells and 7.16 µM for MCF-7 cells. Its inhibitory activity on VEGFR-2 is comparable to Sorafenib (IC50 of 53.63 nM). VEGFR-2-IN-67 exhibits significant anticancer activity by inducing cell apoptosis (with an early apoptosis rate of 57.20%), causing G1 phase cell cycle arrest, upregulating pro-apoptotic markers, and downregulating Bcl-2. This compound is utilized in cancer research.

VEGFR-2-IN-10 has enhanced antiangiogenic potency against VEGFR2 phosphorylation induced by VEGF with an IC50 value of 0.7 μM and no cytotoxic effects.